Valeant Pharmaceuticals International will acquire Solta Medical for $250 million to increase its offerings in the beauty product market, according to a Wall Street Journal report.
Valeant seeks to add Solta's products to its existing portfolio of skin-care treatments. Solta is a developer of medical devices for aesthetics including skin tightening treatment Fraxel and fat loss system Liposonix.
The deal is expected to close in Valeant's fiscal first quarter, according to the report.
MiMedx Group Supports CMS's New Skin Substitute Reimbursement Methodology
Amerinet, Richard Wolf Enter Into Endoscopic Products Partnership
Janssen Therapeutics' OLYSIO Inhibitor Receives FDA Approval for Hepatitis C Treatments
Valeant seeks to add Solta's products to its existing portfolio of skin-care treatments. Solta is a developer of medical devices for aesthetics including skin tightening treatment Fraxel and fat loss system Liposonix.
The deal is expected to close in Valeant's fiscal first quarter, according to the report.
More Articles on Supply Chain:
MiMedx Group Supports CMS's New Skin Substitute Reimbursement Methodology
Amerinet, Richard Wolf Enter Into Endoscopic Products Partnership
Janssen Therapeutics' OLYSIO Inhibitor Receives FDA Approval for Hepatitis C Treatments